Kronos Bio Corp (KRON): Rasio rega marang pendapatan
Kronos Bio, Inc. (KRON) leads in the development of small molecules to combat oncogenic factors, as confirmed by the median P/S. The 5.90 mark captures this metric. Risks are associated with strict ESG controls over laboratory emissions and energy consumption. Business stability relies on retaining leading biologists through stock options and the targeted hiring of clinical research experts.
Kronos Bio Corp (KRON) - rincian metrik lan laporan keuangan
- kuotasi saiki lan rata-rata prakiraan nilai:
- data kapitalisasi bursa:
- statistik nilai buku emiten:
- indikator beban kredit lan likuiditas emiten:
Utang marang Modal Kronos Bio, Inc.|KRON - Rasio utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal Kronos Bio Corporation|KRON - Gunggung utang perusahaan|Utang marang modal buku Kronos Bio Corp|KRON - Utang jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Kronos Bio|Likuiditas darurat kronosbio.com
- data bathi lan kelipatan valuasi:
KRON - Bathi resik perusahaan|Penghasilan resik sing dikarepake Kronos Bio, Inc.|KRON - Pangali P/E|Pangali Forward P/E Kronos Bio Inc|KRON - Rasio rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi operasional sadurunge panyusutan Kronos Bio Corp|KRON - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben siji saham sajrone rolas wulan pungkasan Kronos Bio|KRON - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi EPS kuartalan kronosbio.com|KRON - Wutah bathi saben saham ing taun lumaku|Dinamika bathi saben saham sing diarepake ing taun ngarep Kronos Bio, Inc.
- rincian pendapatan lan dodolan emiten:
Ringkesan analitik perusahaan:kronosbio.com
Optimizing raw material supplies for anti-tumor research ensures Kronos Bio, Inc. (KRON) a stable operating cycle. The current price-to-sales multiple of 5.90 reflects the market valuation of each unit of sales; a sharp increase in this index may indicate the asset is overbought, while undervalued figures often signal hidden fundamental business risks.
Perusahaan pesaing
INCY - Rega marang dodolan|Rasio rega marang pendapatan HUTCHMED HCM|Nuvation Bio Inc - Rasio rega marang pendapatan|DAWN - Rasio rega marang pendapatan|Rega marang dodolan Monopar Corp|INBX: Multiplikator P/S|Multiplikator rega marang pendapatan I-Mab Biopharma IMAB|Kapitalisasi marang pendapatan FENC|Rega marang dodolan Heron Therapeutics Inc HRTX|Kapitalisasi marang pendapatan NVCT (Nuvectis)|CHRS (Coherus BioSciences, Inc) - Rasio kapitalisasi pasar marang pendapatan|Corbus Pharmaceuticals - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan CRDF (Cardiff Oncology Inc.)|BeyondSpring - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan BCAB (BioAtla, Inc.)|LIXT: Multiplikator P/S|Rega marang dodolan Citius Pharmaceuticals, Inc. (CTXR)|Rasio rega marang pendapatan Cellectar Biosciences|BLRX: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S CANF|Multiplikator P/S aprea.com (APRE)|Rasio rega marang pendapatan Kazia Therapeutics Limited KZIA|SLXN (Silexion Therapeutics Corp.) - Rasio rega marang dodolan|NCNA: Kapitalisasi marang pendapatan|Rega marang dodolan chimerix.com|Cyclacel (CYCC) - Rasio rega marang pendapatan|G1 Therapeutics (GTHX) - Multiplikator P/S|Rasio rega marang pendapatan Kintara|ONCT: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Portage Biotech Inc. (PRTG)
